The worldwide MRI industry is expected to be worth more than $5 billion in the next four years with a calculated annual growth rate of 4.56 percent, according to a market report from research firm MarketsandMarkets.

TauRx Therapeutics, the Singapore-based biopharmaceutical company behind a novel tau-modifying Alzheimer’s therapy, is adding 35 new U.S. research sites to its phase III clinical trials network currently researching the drug LMTX as a potential therapy to slow and prevent the progression of Alzheimer’s in patients with mild to moderate cognitive impairment.

Whether to block or leave unblocked was the question when evaluating I-123 meta-iodobenzylguanidine (MIBG) for thyroid uptake. Patients who received thyroid blockade to inhibit absorption of unbound radioiodine during cardiac imaging showed less overall thyroid activity in planar imaging, according to a study published Jan. 2 in the Journal of Nuclear Medicine.

The radiologic and pathologic methods of the past century are being replaced by recent knowledge about disease pathology and genetic specialty, moving away from the appearance of disease toward the expression of genes that play an important role in risk stratification, diagnostics, monitoring disease progression and projecting survival.

The lateral entorhinal cortex has been named the area in the brain where neurodegenerative disease originates, providing new information about how neuronal dysfunction leads to Alzheimer’s progression, according to a study published Dec. 22 in Nature Neuroscience.

Targeted radionuclide therapy could change the whole paradigm used to treat human immunodeficiency virus (HIV), according to one of the most remarkable studies to emerge from the recent Radiological Society of North America (RSNA) annual meeting last month in Chicago.

The health ministers of the G8 countries made an official declaration at the Dementia Summit held at the Lancaster House in London Dec. 11 to develop a viable treatment for Alzheimer’s disease within the next 12 years.

The G8 Dementia Summit held in London Dec. 11 aimed not only at increasing funding research for Alzheimer’s disease, but also approving diagnostic dementia imaging by the U.K.'s National Health Service (NHS).